CD123 Immunohistochemical expression in acute myeloid leukemia is associated with underlying FLT3-ITD and NPM1 mutations

Applied Immunohistochemistry and Molecular Morphology

Volumn 21, Issue 3, 2013, Pages 212-217

  Rollins Raval, Marian ^a   Pillai, Raju ^a   Warita, Katsuhiko ^b   Mitsuhashi Warita, Tomoko ^b   Mehta, Rohtesh ^c   Boyiadzis, Michael ^c   Djokic, Miroslav ^a   Kant, Jeffrey A ^b,d   Roth, Christine G ^a  

^a Division of Hematopathology   (United States)

^b Molecular Diagnostics Laboratory   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

acute myeloid leukemia; CD123; FLT3 ITD; immunohistochemistry; NPM1

Indexed keywords

CD123 ANTIGEN; CD135 ANTIGEN; NUCLEOPHOSMIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BLAST CELL; BONE MARROW BIOPSY; CANCER MORPHOLOGY; CELL DIFFERENTIATION; CHILD; CONTROLLED STUDY; CYTOGENETICS; DISEASE ASSOCIATION; GENE MUTATION; HIGH RISK POPULATION; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; INFANT; INTERNAL TANDEM DUPLICATION; MAJOR CLINICAL STUDY; MOLECULAR PATHOLOGY; MONOCYTE; PREDICTIVE VALUE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOPSY; BONE MARROW; CHILD; CHILD, PRESCHOOL; FEMALE; FMS-LIKE TYROSINE KINASE 3; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; INTERLEUKIN-3 RECEPTOR ALPHA SUBUNIT; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; TANDEM REPEAT SEQUENCES; TUMOR MARKERS, BIOLOGICAL;

EID: 84876980066     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e318261a342     Document Type: Article

References (27)

1. Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116:354-365.
2. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues. . Lyon: IARC; 2008.
3. Estey EH. Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol. 2012;87:89-99.
4. Ravandi F, Kantarjian H, Faderl S, et al. Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse. Leuk Res. 2010;34:752-756.
5. Schlenk RF, Dohner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358:1909-1918.
6. Febbo PG, Ladanyi M, Aldape KD, et al. NCCN Task Force report: evaluating the clinical utility of tumor markers in oncology. qJ Natl Compr Canc Netw. 2011;9(suppl 5):S1-32; quiz S33.
7. Hamid GA, Hanbala N. Comparison of bone marrow aspiration and bone marrow biopsy in neoplastic diseases. Gulf J Oncol. 2009;6:41-44.
8. Talaulikar D, Gray JX, Shadbolt B, et al. A comparative study of the quality of DNA obtained from fresh frozen and formalin-fixed decalcified paraffin-embedded bone marrow trephine biopsy specimens using two different methods. J Clin Pathol. 2008;61: 119-123.
9. Orazi A. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/ myeloproliferative diseases. Pathobiology. 2007;74:97-114.
10. Valbuena JR, Medeiros LJ, Rassidakis GZ, et al. Expression of B cell-specific activator protein/PAX5 in acute myeloid leukemia with t(8;21)(q22;q22). Am J Clin Pathol. 2006;126:235-240.
11. Rollins-Raval MA, Roth CG. The value of immunohistochemistry for CD14, CD123, CD33, myeloperoxidase and CD68R in the diagnosis of acute and chronic myelomonocytic leukaemias. Histopathology. 2012;60:933-942.
12. Jordan CT, Upchurch D, Szilvassy SJ, et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 2000;14:1777-1784.
13. Djokic M, Bjorklund E, Blennow E, et al. Overexpression of CD123 correlates with the hyperdiploid genotype in acute lymphoblastic leukemia. Haematologica. 2009;94:1016-1019.
14. Munoz L, Nomdedeu JF, Lopez O, et al. Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies. Haematologica. 2001;86:1261-1269.
15. Testa U, Riccioni R, Militi S, et al. Elevated expression of IL- 3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. Blood. 2002;100:2980-2988.
16. Riccioni R, Diverio D, Riti V, et al. Interleukin (IL)-3/granulocyte macrophage-colony stimulating factor/IL-5 receptor alpha and beta chains are preferentially expressed in acute myeloid leukaemias with mutated FMS-related tyrosine kinase 3 receptor. Br J Haematol. 2009;144:376-387.
17. Kussick SJ, Stirewalt DL, Yi HS, et al. A distinctive nuclear morphology in acute myeloid leukemia is strongly associated with loss of HLA-DR expression and FLT3 internal tandem duplication. Leukemia. 2004;18:1591-1598.
18. Nomdedeu J, Bussaglia E, Villamor N, et al. Immunophenotype of acute myeloid leukemia with NPM mutations: prognostic impact of the leukemic compartment size. Leuk Res. 2011;35:163-168.
19. Murphy KM, Levis M, Hafez MJ, et al. Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay. J Mol Diagn. 2003;5:96-102.
20. Dohner K, Schlenk RF, Habdank M, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood. 2005;106:3740-3746.
21. Thiede C, Koch S, Creutzig E, et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood. 2006;107:4011-4020.
22. Haferlach T, Bacher U, Alpermann T, et al. Amount of bone marrow blasts is strongly correlated to NPM1 and FLT3-ITD mutation rate in AML with normal karyotype. Leuk Res. 2012;36:51-58.
23. Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005;352:254-266.
24. Xu Y, McKenna RW, Wilson KS, et al. Immunophenotypic identification of acute myeloid leukemia with monocytic differentiation. Leukemia. 2006;20:1321-1324.
25. Riccioni R, Pelosi E, Riti V, et al. Immunophenotypic features of acute myeloid leukaemia patients exhibiting high FLT3 expression not associated with mutations. Br J Haematol. 2011;153:33-42.
26. Vergez F, Green AS, Tamburini J, et al. High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study. Haematologica. 2011;96:1792-1798.
27. Jin L, Lee EM, Ramshaw HS, et al. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell. 2009;5:31-42.